Dafna Capital Management LLC Mereo Biopharma Group PLC Transaction History

Dafna Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.19 - $2.42 $218,603 - $444,554	-183,700 Reduced 19.09%	778,813 $1.8 Million
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $53,474 - $77,655	-46,500 Reduced 4.61%	962,513 $1.24 Million
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $69,125 - $125,125	-87,500 Reduced 7.98%	1,009,013 $1.33 Million
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $39,633 - $202,969	-120,100 Reduced 9.87%	1,096,513 $1.23 Million
Q1 2022 May 16, 2022	BUY	$1.04 - $1.7 $93,600 - $153,000	90,000 Added 7.99%	1,216,613 $1.36 Million
Q2 2021 Aug 16, 2021	SELL	$2.94 - $4.08 $361,722 - $501,982	-123,035 Reduced 9.85%	1,126,613 $3.57 Million
Q1 2021 May 17, 2021	BUY	$2.6 - $4.43 $1.51 Million - $2.58 Million	581,500 Added 87.03%	1,249,648 $4.21 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $914,009 - $1.69 Million	468,723 Added 235.04%	668,148 $2.39 Million
Q3 2020 Nov 16, 2020	BUY	$2.55 - $3.29 $312,693 - $403,436	122,625 Added 159.67%	199,425 $522,000
Q2 2020 Aug 14, 2020	BUY	$1.0 - $3.4 $76,800 - $261,120	76,800 New	76,800 $235,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $376M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.